Last reviewed 2026-04-19 · How we verify

ABT-126

ABT-126 is being studied as a potential treatment for mild to moderate Alzheimer's disease in clinical trials.

ABT-126 is a new treatment being evaluated for Mild to Moderate Alzheimer's Disease. Clinical trials are currently underway to assess its efficacy and safety. These trials also examine its pharmacokinetic properties and impact on biomarkers.

At a glance

Mechanism of action

The provided text does not contain information about the mechanism of action of ABT-126. Therefore, a plain English explanation cannot be generated from the source data.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) (Phase 2)
• A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsm (Phase 2)
• A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease (Phase 2)
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers (Phase 2)
• Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855 (Phase 2)
• A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease (Phase 2)
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibi (Phase 2)
• NCT00959634 (Phase 1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.